VIDEO: Treatment options limited after EGFR-mutated lung cancer relapse

Editor’s note: This is an automatically generated transcript. Please notify editor@healio.com if there are concerns regarding accuracy of the transcription.

We still have a lot of unmet need. As I said, the frontline setting, we start to accomplish even longer progression-free survival. We start to see overall survival benefit. But once EGFR metastatic lung cancer patient relapse after the frontline, our treatment options are still quite limited. Statistics tells us that once the patient relapse, their survival from that time on is only around a year, which is really devastating. So I think developing more effective agents after TKI resistance, to me, is very important for patients, for physician, for prolonging life. One particular clinical challenge I will have to highlight here is that brain metastasis is a common phenomena for lung cancer patients. For EGFR mutation patients, the incidence can be as high as 50% or above. So that population of patients is also a large unmet need.